Forbes contributors publish independent expert analyses and insights. Dr. Lance B. Eliot is a world-renowned AI scientist and consultant. In today’s column, I am continuing my ongoing coverage of ...
Revuforj shows a 63.9% overall response rate in relapsed/refractory KMT2Ar acute leukemia, with significant MRD negativity and HSCT progression rates. The AUGMENT-101 trial reports a median duration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback